Rockwell Medical, Inc. (DE) Common Stock (RMTI) Stock Price

RMTIStock

$7.43−37.56%52W

Market Cap$29.95M

P/E—

PEG Ratio4.43

Div yield—

Beta1.71

RMTI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-29.75%

Price vs S&P 500 (4W)-13.27%

PEG Ratio4.43

VGM Score58.16

P/CF (Annual)8.97x

Book Value / Share (Quarterly)$8.83

P/TBV (Annual)1.20x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-1.65%

Cash Flow / Share (Quarterly)$0.39

Price vs S&P 500 (YTD)-22.84%

Gross Margin (TTM)18.72%

Net Profit Margin (TTM)-7.33%

EPS (TTM)$-1.33

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-1.33

Revenue Growth (5Y)2.17%

EPS (Annual)$-1.48

ROI (Annual)-11.34%

Gross Margin (Annual)18.62%

Net Profit Margin (5Y Avg)-19.33%

Cash / Share (Quarterly)$6.24

Revenue Growth QoQ (YoY)10.63%

ROA (Last FY)-9.30%

Revenue Growth TTM (YoY)-21.12%

EBITD / Share (TTM)$-0.63

ROE (5Y Avg)-294.82%

Operating Margin (TTM)-6.52%

Cash Flow / Share (Annual)$-0.30

P/B Ratio0.85x

P/B Ratio (Quarterly)0.62x

Net Income / Employee (Annual)$-33,800

EV / Revenue (TTM)0.42x

Net Interest Coverage (TTM)-7.53x

ROA (TTM)-8.90%

EV / EBITDA (TTM)32.33x

EPS Incl Extra (Annual)$-1.48

Current Ratio (Annual)3.98x

Quick Ratio (Quarterly)2.96x

3-Month Avg Trading Volume0.03M

52-Week Price Return-37.56%

EV / Free Cash Flow (Annual)10.71x

Revenue / Employee (TTM)$442,000

Tangible BV / Share (Quarterly)$6.47

P/S Ratio (Annual)0.43x

Asset Turnover (Annual)1.21x

52-Week High$12.90

Operating Margin (5Y Avg)-17.24%

EPS Excl Extra (Annual)$-1.48

CapEx CAGR (5Y)-12.39%

Tangible BV CAGR (5Y)-3.65%

26-Week Price Return-19.85%

Quick Ratio (Annual)3.46x

13-Week Price Return21.31%

Total Debt / Equity (Annual)0.27x

Current Ratio (Quarterly)3.25x

Enterprise Value$28.97M

Revenue / Share Growth (5Y)16.29%

Asset Turnover (TTM)1.21x

Book Value / Share Growth (5Y)18.51%

Revenue / Employee (Annual)$441,100

Inventory Turnover (Annual)12.25x

Pretax Margin (Annual)-7.67%

Cash / Share (Annual)$6.34

3-Month Return Std Dev52.37%

Gross Margin (5Y Avg)9.59%

Net Income / Employee (TTM)$-32,400

ROE (Last FY)-14.37%

Net Interest Coverage (Annual)-8.06x

EPS Basic Excl Extra (Annual)$-1.48

P/FCF (TTM)8.16x

Receivables Turnover (TTM)8.47x

EV / Free Cash Flow (TTM)18.81x

Total Debt / Equity (Quarterly)0.27x

EPS Incl Extra (TTM)$-1.33

Receivables Turnover (Annual)8.43x

ROI (TTM)-11.05%

P/S Ratio (TTM)0.43x

Pretax Margin (5Y Avg)-19.33%

Revenue / Share (Annual)$19.25

Tangible BV / Share (Annual)$6.93

Price vs S&P 500 (52W)-53.09%

Year-to-Date Return-10.91%

5-Day Price Return-1.85%

EPS Normalized (Annual)$-1.48

ROA (5Y Avg)-26.72%

Net Profit Margin (Annual)-7.67%

Month-to-Date Return-13.00%

Cash Flow / Share (TTM)$-0.70

EBITD / Share (Annual)$-0.69

Operating Margin (Annual)-6.77%

LT Debt / Equity (Annual)0.24x

P/CF (TTM)10.34x

ROI (5Y Avg)-51.24%

LT Debt / Equity (Quarterly)0.21x

EPS Basic Excl Extra (TTM)$-1.33

P/TBV (Quarterly)0.85x

P/B Ratio (Annual)0.89x

Inventory Turnover (TTM)16.17x

Pretax Margin (TTM)-7.33%

Book Value / Share (Annual)$9.38

Price vs S&P 500 (13W)18.62%

Beta1.71x

P/FCF (Annual)9.38x

Revenue / Share (TTM)$17.53

ROE (TTM)-14.03%

52-Week Low$4.88

vGradeB

gGradeD

mGradeB

vgmGradeC

RMTI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.23	-$0.34	-44.68%(-$0.11)
Q1 2026	May 7, 2026	-$0.25	-$0.40	-60.00%(-$0.15)
Q4 2025	Mar 26, 2026	$0.20	-$0.10	-150.00%(-$0.30)
Q3 2025	Nov 12, 2025	-$0.45	-$0.50	-11.11%(-$0.05)
Q2 2025	Aug 14, 2025	-$0.50	-$0.50	+0.00%(+$0.00)

RMTI Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RMTIRockwell Medical, Inc. (DE) Common Stock	B	D	B	0.4x	-21.1%	18.7%	—	$7.43
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Rockwell Medical, Inc. (DE) Common Stock

Rockwell Medical Inc manufactures and distributes dialysis concentrates—essential consumables used in hemodialysis treatment. The company supplies liquid and dry bicarbonate and acid formulations, including CitraPure, RenalPure, and SteriLyte, to dialysis providers across the United States. It operates in a stable, recurring-revenue market driven by the ongoing treatment needs of dialysis patients.

RMTI Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeBMO

Revenue estimate$18.22M

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

RMTI Insider Transactions

SellOct 1, 2026
STROBECK MARK
Chief Executive Officer
Shares: 1,000Value: $8,420

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

CVMCel-Sci CorporationBiological Products
UGUnited-Guardian, Inc.Cosmetics & Toiletries
AVDAmerican Vanguard CorporationAgricultural Chemicals
ALGSAligos Therapeutics, Inc. Common StockBiological Products
MGXMetagenomi Therapeutics, Inc. Common StockBiological Products
EVAXEvaxion A/S American Depositary ShareBiological Products
BKHABlack Hawk Acquisition Corporation Class A Ordinary SharesBiological Products
SCLXScilex Holding Company Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$4.88

High$12.90